Gynecologic Cancer

Top Story

FDA approves Lynparza for ovarian cancer maintenance therapy

August 17, 2017

The FDA today granted regular approval to olaparib tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved complete or partial response to platinum-based chemotherapy.

The approval of olaparib (Lynparza, AstraZeneca) — a poly ADP ribose polymerase (PARP) inhibitor — coincides with the introduction of a tablet formulation.

Addition of CA4P to bevacizumab confers modest PFS benefit in platinum-resistant ovarian cancer

August 17, 2017
A second interim analysis of a trial designed to evaluate the addition of CA4P to standard therapy for patients with platinum-resistant ovarian cancer showed a small PFS…

Clinical trial stirs controversy over power morcellator bags

August 16, 2017
A clinical trial scheduled to evaluate the safety and efficacy of a bag designed to catch cancerous tissue from power morcellation in women undergoing laparoscopic…
In the Journals Plus

Older patients with cancer may burden caregivers by overestimating physical abilities

August 14, 2017
Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study…
More Headlines »
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Video
Meeting News Coverage

VIDEO: Combination therapy with PD-L1, PARP inhibitors appears effective in patients with ovarian, breast cancer

September 8, 2016
More »
Resource Centers

CME

The Patient with Myelofibrosis

No commercial support for this activity.

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature…
More »
Advertisement
Advertisement